Date published:
Audience:
General public
When COVID-19 symptoms persist after 12 weeks, this is called Post-Acute Sequelae of COVID-19 (PASC)—or long COVID. Having PASC can affect your ability to live your life normally and do your usual daily activities.
Health experts are still learning about this condition.
The MRFF’s 2026 PASC grant opportunity is providing up to $23 million for medical research and innovation projects that:
- investigate the biological pathways and causes of PASC subtypes to better design interventions and improve clinical outcomes
- carry out pre-clinical or early-phase clinical research to improve our understanding of PASC subtypes and inform the development of medicinal and non-medicinal treatments
- compare the underlying causes of PASC with illnesses that happen after a viral infection, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Postural Orthostatic Tachycardia Syndrome (POTS), and fibromyalgia. These will be small-scale projects
- identify scalable, sustainable integrated care approaches for people with PASC, and evaluate their effectiveness and feasibility across health system settings. This will be a large-scale project.
Funding is from the MRFF’s Emerging Priorities and Consumer-Driven Research initiative.
Visit GrantConnect and the MRFF calendar for information on all MRFF grant opportunities.
Explore the MRFF.